Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 23, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transfer of 5,332 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on December 22, 2004, and the company was advised of it on December 23, 2004.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—are interested in the shares held in the trust in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares transferred (5,332) and the specific plan involved (SmithKline Beecham Employee Share Option Plan 1991).
- Confirm the identities of the directors with interests in the GSK Trust: Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe.
- Note that this filing does not contain financial results; refer to the company's Form 20-F for comprehensive financial data.